

25 March 2025

Osteopore opens knee preservation clinical centre of excellence

Highlights

- Osteopore sets up clinical centre of excellence (CCoE) for medial wedge opening high tibial osteotomy (MOWHTO) with Total Orthopaedics.
- Distinguished consultant orthopaedic surgeon Dr Hamid Razak, a key opinion leader on Osteopore's clinical advisory panel, will lead the CCoE.
- The CCoE is focused on medial wedge opening high tibial osteotomy (MOWHTO) and post-surgery rehabilitation.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the opening of a Clinical Centre of Excellence (CCoE) for medial wedge opening high tibial osteotomy (MOWHTO), in partnership with Total Orthopaedic Care & Surgery's Dr Hamid Razak.

This announcement comes on the back of the recent approval of Osteopore's orthopaedic product in Singapore¹ and the signing of DKSH as a strategic partner², highlighting our ongoing commitment to advancing orthopaedic care and improving patient outcomes in knee preservation.

¹ ASX Announcement, Osteopore secures Singapore and Vietnam market approvals, 27 Mar 2024.

² ASX Announcement, Osteopore inks DKSH deal to sell ortho products in Singapore, 6 Nov 2024.

Total Orthopaedic Care & Surgery is a specialist orthopaedic clinic in Singapore, recognised for its broad, evidence-based and patient-centred approach to orthopaedic and musculoskeletal care, combined with less invasive techniques, quality and accessibility.

Dr Hamid, a distinguished consultant orthopaedic surgeon with more than 15 years of experience, also serves as an Adjunct Associate Professor at Duke-NUS Medical School. He is a key opinion leader (KOL) on Osteopore's clinical advisory board, contributing his vast expertise to the CCoE.

Previously, Dr Hamid led Sports & Joint Preserving Osteotomy Services at Sengkang General Hospital and served as the site chief for the SingHealth Sports & Exercise Medicine Centre. Dr Hamid has completed fellowships at Imperial College London and the London Knee Osteotomy Centre and has been awarded the prestigious College Travelling Fellowship by Glasgow's Royal College of Physicians & Surgeons, as well as the ICRS Clinical Travelling Fellowship. His extensive training includes proficiency in joint preservation procedures and the use of the Oxford Partial Knee implant.

This CCoE is dedicated to improving the understanding and adoption of MOWHTO among clinicians for relevant patients. The CCoE will serve as a training hub, providing educational sessions led by Dr Hamid, focusing on the MOWHTO technique and post-surgery rehabilitation protocols, ensuring clinicians are equipped to deliver optimal care.

MOWHTO is one of the surgical options under the broader category of knee preservation techniques. These techniques are gaining popularity globally as they offer joint preservation and minimal trauma, effectively delaying the need for total knee arthroplasty (TKA) by several years³. Recent studies highlight the growing trend in knee preservation, emphasising advancements in surgical strategies and technologies that enhance patient outcomes⁴.

³ Seil et al., doi.org/10.1007/s00167-012-2175-3

⁴ He et al., doi.org/10.1186/s13643-021-01601-z

Osteopore's MOWHTO product was compared in a head-to-head clinical study against allogeneic femoral head grafts, outperforming the allogeneic grafts in bone union⁵.

The MOWHTO market is expected to grow at a CAGR of 9.2%, with procedures projected to reach 35,000 annually in the Asia Pacific region (APAC) by 2025⁶ according to market research.

Commenting on this partnership, Osteopore CEO Dr Lim Yujing, said:

"Training and education are vital to ensuring that innovative products are used with the most appropriate surgical techniques.

"We are honoured to have Dr Hamid's expertise in knee preservation and MOWHTO, and we look forward to a successful partnership."

Commenting on this partnership, Dr Hamid Razak, said:

"I am dedicated to advancing knee preservation through collaborative research and innovation with like-minded surgeons, researchers, and industry partners.

"Establishing this Centre with Osteopore is a natural step in this mission. I look forward to a strong partnership that will drive innovation and enhance patient care in knee preservation."

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Isaac Stewart

Media & Investor Relations

Purple

E: istewart@purple.au

⁵ Chua et al., doi: 10.1177/19476035241246609

⁶ Commissioned research (data on file), 2020.

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

About Total Orthopaedics

Total Orthopaedic Care & Surgery is an orthopaedic specialist clinic in Singapore dedicated to providing comprehensive, evidence-based orthopaedic and musculoskeletal care to patients, with a focus on patient care, minimally invasive techniques, quality and accessibility.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement.

This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.